The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment
Open accessAbstract
Given the introduction of new therapies targeting specific immune pathways for atopic dermatitis (AD), information on the economic burden of AD patients is needed. Direct costs (medication use and healthcare resource utilization) and costs of productivity loss were studied in 90 adult patients with AD indicated for systemic treatment. Costs were calculated for patients with controlled (Investigator Global Assessment (IGA) 0-2) and uncontrolled (IGA 3-5) disease at inclusion. Mean (95% confidence interval (95% CI)) total direct costs were €5,191 (€4,382-6,019) per patient per year (PPY), €4,401 (€3,695-5,215) for patients with controlled AD vs. €6,993 (€5,552-8,406), mean difference €2,593 (€820-4,282) (p=0.014) for patients with uncontrolled AD. Costs of productivity loss were €10,040 (€6,260-14,012) PPY for the total group, €6,886 (€4,188-10,129) PPY for patients with controlled AD vs. €13,702 (€6,124-22,996) for patients with uncontrolled AD, mean difference €6,816 (-€1,638-16,677; p=0.148). Total costs (direct costs+costs of productivity loss) were €15,231 (€11,487-19,455) PPY for the total group, €11,287 (€7,974-15,436) for patients with controlled AD vs. €20,695 (€14,068-34,564), mean difference €9,408 (-€119-19,964) (p=0.077) for patients with uncontrolled AD. Patients with AD using systemic immunosuppressive treatment incur considerable direct costs and costs of productivity loss.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Diagnostic features of atopic dermatitis
Hanifin, J. M., & Rajka, G. (1980) · Acta Dermato-Venereologica · doi:10.2340/00015555924447 · Cited by 5,086
The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument
Reilly, M. C., Zbrozek, A. S., & Dukes, E. M. (1993) · PharmacoEconomics · doi:10.2165/00019053-199304050-00006 · Cited by 3,071
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
WILLIAMS, H. C., JBURNEY, P. G., HAY, R. J., ARCHER, C. B., SHIPLEY, M. J., AHUNTER, J. J., BINGHAM, E. A., FINLAY, A. Y., PEMBROKE, A. C., CGRAHAM-BROWN, R. A., et al. (1994) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1994.tb08530.x · Cited by 1,271
Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Self-citationEpidemiology of atopic dermatitis in adults: Results from an international survey
Barbarot, S., Auziere, S., Gadkari, A., Girolomoni, G., Puig, L., Simpson, E. L., Margolis, D. J., de Bruin‐Weller, M., & Eckert, L. (2018) · Allergy · doi:10.1111/all.13401 · Cited by 876
Self-citationChren, M.-M., Lasek, R. J., Quinn, L. M., Mostow, E. N., & Zyzanski, S. J. (1996) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12365600 · Cited by 699
Chren, M.-M. (1997) · Archives of Dermatology · doi:10.1001/archderm.1997.03890470111018 · Cited by 480
Chren, M. (1997) · Archives of Dermatology · doi:10.1001/archderm.133.11.1433 · Cited by 446
Simpson, E. L., Bieber, T., Eckert, L., Wu, R., Ardeleanu, M., Graham, N. M. H., Pirozzi, G., & Mastey, V. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.10.043 · Cited by 302
Cited by
Langan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Wollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
Self-citationType 2 chronic inflammatory diseases: targets, therapies and unmet needs
Kolkhir, P., Akdiş, C. A., Akdiş, M., Bachert, C., Bieber, T. R. M., Canonica, G. W., Guttman‐Yassky, E., Metz, M., Mullol, J., Palomares, Ó., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00750-1 · Cited by 194
Burden of Atopic Dermatitis in Adults and Adolescents: a Systematic Literature Review
Fasseeh, A. N., Elezbawy, B., Korra, N., Tannira, M., Dalle, H., Aderian, S., Abaza, S., & Kaló, Z. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00819-6 · Cited by 158
“The total indirect cost per patient was reported in three studies with an average cost of 9068 USD per year [72, 76, 88].”
Background
Metadata
- Authors
- Ariëns, L., Nimwegen, K., Shams, M., Bruin, D., Schaft, J., Os-Medendorp, H., & Bruin-Weller, M.
- Affiliations
- University Medical Center Utrecht (NL)
- Pharmerit (Netherlands) (NL)
- Sanofi (Netherlands) (NL)
- ORCID
- Ariëns, L
- Venue
- Acta Dermato Venereologica
- Published
- 2019
- Volume
- 99
- Issue
- 9
- Pages
- 762-768
- ISSN
- 0001-5555 (ISSN-L)
- OpenAlex
- W2944714946
- Cited by
- 79
- References
- 21
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 12 · 2023: 12 · 2022: 14 · 2021: 13 · 2020: 10
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Acta Dermato Venereologica (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Sanofi Genzyme
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Keywords
- atopic dermatitis, economic burden, direct costs, productivity loss, systemic immunosuppressive therapy, disease control, healthcare resource utilization, drug costs, adults
- MeSH terms
- Absenteeism, Work Performance, Presenteeism, Adult, Age Factors, Dermatitis, Atopic, Dermatologic Agents, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Severity of Illness Index, Time Factors, Drug Costs, Treatment Outcome, Cost of Illness, Sick Leave
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment. https://app.cochat.ai/papers/10.2340/00015555-3212
- The paper
- Ariëns, L., Nimwegen, K., Shams, M., Bruin, D., Schaft, J., Os-Medendorp, H., & Bruin-Weller, M. (2019). Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment. Acta Dermato Venereologica. https://doi.org/10.2340/00015555-3212
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.